Charles Schwab Investment Management Inc. Has $2.24 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Charles Schwab Investment Management Inc. lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 3.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 89,626 shares of the company’s stock after selling 2,782 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Kiniksa Pharmaceuticals were worth $2,240,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Rubric Capital Management LP grew its holdings in Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock valued at $45,165,000 after purchasing an additional 223,094 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after purchasing an additional 157,741 shares during the period. Rice Hall James & Associates LLC lifted its position in Kiniksa Pharmaceuticals by 8.2% in the third quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock worth $16,234,000 after purchasing an additional 49,000 shares during the period. Millennium Management LLC lifted its position in Kiniksa Pharmaceuticals by 159.8% in the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Kiniksa Pharmaceuticals by 40.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 324,064 shares of the company’s stock worth $8,098,000 after purchasing an additional 92,985 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on KNSA shares. JPMorgan Chase & Co. raised their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Evercore ISI lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Stock Up 0.3 %

Shares of KNSA stock opened at $20.20 on Monday. The stock has a 50-day moving average price of $23.25 and a 200 day moving average price of $23.10. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -144.29 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same quarter last year, the business posted ($0.20) EPS. Kiniksa Pharmaceuticals’s quarterly revenue was up 67.4% on a year-over-year basis. Sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the sale, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 17,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the sale, the chief operating officer now owns 109,975 shares in the company, valued at $2,955,028.25. The trade was a 13.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 44,592 shares of company stock worth $1,110,364 in the last 90 days. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.